|Dr. Mark Pruzanski||Founder, CEO, Pres & Director||1.15M||4.62M||1968|
|Mr. Sandip S. Kapadia||CFO, Treasurer & Principal Accounting Officer||693.14k||N/A||1970|
|Mr. Jerome B. Durso||Chief Operating Officer||855.24k||N/A||1968|
|Mr. Ryan T. Sullivan||Gen. Counsel & Sec.||812.95k||N/A||1976|
|Dr. Gail Cawkwell||Sr. VP of Medical Affairs, Safety & Pharmacovigilance||600.85k||N/A||1962|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 10.